Skip to main content
Quest Diagnostics

4 critical steps to optimize cancer diagnosis

Article

read time: 8 minutes

Topics:

Pathology & Laboratory Medicine

In the fight against cancer, survival rates improve dramatically when cancer is diagnosed early and the disease can be limited to its point of origin.1 Liquid biopsy testing shows potential to improve and accelerate cancer diagnosis by identifying certain biomarkers circulating in the blood that indicate the presence of tumors. The broad availability of well-validated and affordable laboratory blood tests that can identify several cancers at once would be a major advancement for cancer screening and patient outcomes. In this article for CLP, Yuri Fesko MD, vice president for Medical Affairs at Quest Diagnostics, outlines 4 steps to clear the way for these potential technologies.

Read 4 Critical Steps to Optimize Cancer Diagnosis on clpmag.com

Read article
Page Published: November 10, 2022
1 EarlyDetectionFactSheet.pdf (canaryfoundation.org)

On-Demand Webinar
How to close gaps in care by maximizing the power of laboratory stewardship solutions
Article
Balancing the desire for quick AML results with precision genetic testing
Increasing patient compliance through a holistic post-transplant testing program

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.